Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma

International Journal of Cancer

Volumn 137, Issue 4, 2015, Pages 810-818

  Nogueira, Guilherme Augusto Silva ^a   Lourenço, Gustavo Jacob ^a   Oliveira, Camila Borges Martins ^a   Marson, Fernando Augusto Lima ^a   Lopes Aguiar, Leisa ^a   Costa, Ericka Francislaine Dias ^a   Lima, Tathiane Regine Penna ^a   Liutti, Vitor Teixeira ^a   Leal, Frederico ^a   Santos, Vivian Castro Antunes ^a   Rinck Junior, José Augusto ^a   Lima, Carmen Silvia Passos ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

DNA mismatch repair; EXO1; head and neck squamous cell carcinoma; laryngeal squamous cell carcinoma; MLH1; MSH2; MSH3; prognosis; risk; SNP

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; EXO1 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HETEROZYGOTE; HUMAN; LARYNX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MLH1 GENE; MSH2 GENE; MSH3 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TOBACCO; ADOLESCENT; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; GENETIC ASSOCIATION STUDIES; GENETICS; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EXO1 PROTEIN, HUMAN; EXODEOXYRIBONUCLEASES; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; MSH3 PROTEIN, HUMAN; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EXODEOXYRIBONUCLEASES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84931572996     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29435     Document Type: Article

References (42)

1. Sturgis EM,. International Head and Neck Cancer Epidemiology Consortium: update no. 9. Head Neck 2013; 35: 2-3.
2. Hecht SS., Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 10: 733-44.
3. Hang B., Formation and repair of tobacco carcinogen-derived bulky DNA adducts. J Nucleic Acids 2010; 2010: 29 p.
4. Cloos J, Spitz MR, Schantz SP, et al., Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88: 530-5.
5. Harfe BD, Jinks-Robertson S., DNA mismatch repair and genetic instability. Annu Rev Genet 2000; 34: 359-99.
6. Kunkel TA, Erie DA., DNA mismatch repair. Annu Rev Biochem 2005; 74: 681-710.
7. Jiricny J., The multifaceted mismatch-repair system. Nature Rev Mol Cell Biol 2006; 7: 335-46.
8. Mohrenweiser HW, Jones IM., Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? Mutat Res 1998; 400: 15-24.
9. Berwick M, Vineis P., Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000; 92: 874-97.
10. Perera S, Mrkonjic M, Rawson JB, et al., Functional effects of the MLH1-93G>A polymorphism on MLH1/EPM2AIP1 promoter activity. Oncol Rep 2011; 25: 809-15.
11. Marra G, D'atri S, Corti C, et al., Tolerance of human MSH2+/- lymphoblastoid cells to the methylating agent temozolomide. Proc Natl Acad Sci USA 2001; 98: 7164-9.
12. Jin G, Wang H, Hu Z, et al., Potentially functional polymorphisms of EXO1 and risk of lung cancer in a Chinese population: a case-control analysis. Lung Cancer 2008; 60: 340-6.
13. Berndt SI, Platz EA, Fallin MD, et al., Mismatch repair polymorphisms and the risk of colorectal cancer. Int J Cancer 2007; 120: 1548-54.
14. Koessler T, Oestergaard MZ, Song H, et al., Common variants in mismatch repair genes and risk of colorectal cancer. Gut 2008; 57: 1097-101.
15. Vogelsang M, Wang Y, Veber N, et al., The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PLoS One 2012; 7: e36962.
16. Jha R, Gaur P, Sharma SC, et al., Single nucleotide polymorphism in hMLH1 promoter and risk of tobacco-related oral carcinoma in high-risk Asian Indians. Gene 2013; 526: 223-7.
17. Tsai MH, Tseng HC, Liu CS, et al., Interaction of Exo1 genotypes and smoking habit in oral cancer in Taiwan. Oral Oncol 2009; 45: 90-4.
18. Marcopito LF, Coutinho AP, Valencich DM, et al., Exposition to smoking and attitudes: comparison between inquiries applied to adult population in São Paulo city, 1987 and 2002. Arq Bras Cardiol 2007; 89: 333-40.
19. Carvalho ALH, Hildebrand LC, Haas AN, et al., Head and neck squamous cell carcinoma: decline in clinical stage at the time of diagnosis in a reference hospital in southern Brazil. Appl Cancer Res 2012; 32: 111 -1 5.
20. Hayes RB, Bravo-Otero E, Kleinman DV, et al., Tobacco and alcohol use and oral cancer in Puerto Rico. Cancer Causes Control 1999; 10: 27-33.
21. Mori S, Nose M, Morikawa H, et al., A novel evaluation system of metastatic potencial of oral squamous cell carcinoma according to the histopathological and histochemical grading. Oral Oncol 1998; 34: 549-57.
22. American Joint Committee on Cancer. Cancer staging handbook from the AJCC cancer staging manual, 7th edn. Philadelphia: Springer, 2010. 21-97.
23. Pignon JP., Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-55.
24. Adelstein DJ, Li Y, Adams GL, et al., An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2001; 21: 92-8.
25. Forastiere AA, Metch B, Schuller DE, et al., Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-51.
26. Bernier J, Domenge C, Ozsahin M, et al., Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004: 350: 1945-52.
27. Park SH, Lee GY, Jeon HS, et al.,-93G>A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer 2004; 112: 678-82.
28. Jung CY, Choi JE, Park JM, et al., Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 762-8.
29. Livak KJ, Schmittgen TD., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
30. Hahn LW, Ritchie MD, Moore JH., Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19: 376-82.
31. Moore JH, Gilbert JC, Tsai CT, et al., A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 2006; 241: 252-61.
32. Ritchie MD, Hahn LW, Moore JH., Power of multifactor dimensionality reduction for detecting gene-gene interactions in the presence of genotyping error, missing data, phenocopy, and genetic heterogeneity. Genet Epidemiol 2003; 24: 150-7.
33. Carvalho-Silva DR, Santos FR, Rocha J, et al., The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet 2001; 68: 281-6.
34. Drabløs F, Feyzi E, Aas PA, et al., Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair 2004; 3: 1389-407.
35. Drummond JT, Genschel J, Wolf E, et al., DHFR/MSH3 amplification in methotrexate-resistant cells alters the hMutSalpha/hMutSbeta ratio and reduces the efficiency of base-base mismatch repair. Proc Natl Acad Sci USA 1997; 94: 10144-9.
36. Chen L, Yang Y, Liu S, et al., High expression of leucine zipper-EF-hand containing transmembrane protein 1 predicts poor prognosis in head and neck squamous cell carcinoma. Biomed Res Int 2014; 2014: 850316.
37. Shiga H, Heath EI, Rasmussen AA, et al., Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999; 5: 4097-104.
38. Chang MF, Wang HM, Kang CJ, et al., Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary-an experience in Taiwan. Radiat Oncol 2010; 5: 91.
39. Bədulescu F, Bədulescu A, Crişan A, et al., Study of the diagnosis and treatment of cancer located in the head and neck and correlation with expression of prognostic markers. Rom J Morphol Embryol 2013; 54: 487-97.
40. Bolderson E, Tomimatsu N, Richard DJ, et al., Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res 2010; 38: 1821-31.
41. Pepponi R, Graziani G, Falcinelli S, et al., hMSH3 overexpression and cellular response to cytotoxic anticancer agents. Carcinogenesis 2001; 22: 1131-7.
42. Takahashi M, Koi M, Balaguer F, et al., MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem 2011; 286: 12157-65.